Surendra Barshikar, MD
Physical Medicine & Rehabilitation · Dallas, TXNPI 1366684920
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Otsuka America Pharmaceutical, Inc. accounts for 72.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $7,881 and has fallen 98.6% since, to $108 in 2025. Among physical medicine & rehabilitation clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $192.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$8K
- AbbVie$988
- Avanir Pharmaceuticals, Inc.$947
- Ipsen Biopharmaceuticals, Inc$479
- MDD US Operations, LLC$153
- Merz North America, Inc.$153
- plus $304 from 5 others
Across 52 payments — averaging $2388.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$50K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$49K
- CSL Behring$26K
What the payments were for
- Consulting fees$6,18657%
- Travel & lodging$1,92618%
- Food & beverage$2,27221%
- Education$4054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $7,765 |
| AbbVie(2 entities) | 16 | $988 |
| Avanir Pharmaceuticals, Inc. | 11 | $947 |
| Ipsen Biopharmaceuticals, Inc | 7 | $479 |
| MDD US Operations, LLC | 3 | $153 |
| Merz North America, Inc. | 2 | $153 |
| Saol Therapeutics Inc. | 2 | $116 |
| CSL Behring | 2 | $86 |
| Pacira Pharmaceuticals Incorporated | 1 | $73 |
| Tersera Therapeutics LLC | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUEDEXTA$7,544
- BOTOX COSMETIC$300
- BOTOX$273
- MYOBLOC$127
- XEOMIN$117
How this compares
$10,789 in reported general payments places this provider in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 50 | $2,324 |
| AmantadineAmantadine Hcl | 16 | $739 |
| Gabapentin | 26 | $493 |
| Duloxetine Hcl | 21 | $310 |
| Amitriptyline Hcl | 13 | $229 |
| Tizanidine Hcl | 12 | $174 |
| Trazodone Hcl | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Dallas
- Gireesh ShardaDallas$172K
- Fatma GulDallas$21K
- Priya ChittaDallas$15K
- Nikesh PatelDallas$14K
- Rinoo ShahDallas$7K
- Gerard FranciscoHouston$364K
- Jose UrquidezAustin$332K
- Suzanne ManziHouston$143K
- Cindy IvanhoeHouston$111K
- Chad McNeilTyler$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.